338 related articles for article (PubMed ID: 21200381)
1. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
3. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
Xie Y; Zhang X; Zhao T; Li W; Xiang J
Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
[TBL] [Abstract][Full Text] [Related]
4. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
6. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.
Hao S; Bai O; Li F; Yuan J; Laferte S; Xiang J
Immunology; 2007 Jan; 120(1):90-102. PubMed ID: 17073943
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
8. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
9. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Chibbar R; Wei Y; Liu Q; Xiang J
Vaccine; 2011 Apr; 29(19):3538-47. PubMed ID: 21406265
[TBL] [Abstract][Full Text] [Related]
10. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
[TBL] [Abstract][Full Text] [Related]
11. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
Xiang J; Huang H; Liu Y
J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
[TBL] [Abstract][Full Text] [Related]
12. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
13. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
15. Acquired pMHC I complexes greatly enhance CD4(+) Th cell's stimulatory effect on CD8(+) T cell-mediated diabetes in transgenic RIP-mOVA mice.
Ahmed KA; Xie Y; Zhang X; Xiang J
Cell Mol Immunol; 2008 Dec; 5(6):407-15. PubMed ID: 19118506
[TBL] [Abstract][Full Text] [Related]
16. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities.
Yao Y; Chen L; Wei W; Deng X; Ma L; Hao S
Biochem Biophys Res Commun; 2013 Jun; 436(1):60-5. PubMed ID: 23707941
[TBL] [Abstract][Full Text] [Related]
18. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity.
Zhang X; Huang H; Yuan J; Sun D; Hou WS; Gordon J; Xiang J
J Immunol; 2005 Sep; 175(5):2931-7. PubMed ID: 16116179
[TBL] [Abstract][Full Text] [Related]
19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
20. Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired peptide-MHC class I complexes.
Hao S; Yuan J; Xu S; Munegowda MA; Deng Y; Gordon J; Xing Z; Xiang J
J Immunol; 2008 Aug; 181(4):2428-37. PubMed ID: 18684933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
